<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219307</url>
  </required_header>
  <id_info>
    <org_study_id>AAG-G-H-1703</org_study_id>
    <nct_id>NCT03219307</nct_id>
  </id_info>
  <brief_title>NOVOCART 3D Treatment Following Microfracture Failure</brief_title>
  <official_title>Safety and Efficacy of NOVOCART 3D in the Treatment of Articular Cartilage Defects Following Failure on Microfracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aesculap Biologics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aesculap Biologics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open
      only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an extension of protocol AAG-G-H-1220 wherein patients were randomized to
      either NOVOCART 3D or Microfracture treatment groups. This prospective single arm extension
      study is only open to participants of AAG-G-H-1220 who were randomized to Microfracture
      treatment and who failed Microfracture treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KOOS pain subdomain score</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of pain scores from the KOOS questionnaire from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>KOOS function subdomain score</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of function scores from the KOOS questionnaire from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS pain scale</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of pain from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IKDC subjective scores</measure>
    <time_frame>24 months</time_frame>
    <description>Comparison of IKDC subjective scores from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Articular Cartilage Defect</condition>
  <arm_group>
    <arm_group_label>NOVOCART 3D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Matrix associated autologous chondrocyte implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>NOVOCART 3D</intervention_name>
    <description>Matrix associated autologous chondrocyte implant</description>
    <arm_group_label>NOVOCART 3D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  participated in study AAG-G-H-1220

          -  identified as a microfracture failure patient

          -  voluntary consent to participate in the study

        Exclusion Criteria:

          -  other cartilage repair procedures performed on target knee

          -  other conditions that would interfere with healing or evaluating outcomes

          -  lesions requiring implants larger than 9cm2

          -  non-compliance with requirements in study AAG-G-H-1220
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Spiro, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Aesculap Biologics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Sisler, BSN, RN</last_name>
    <phone>610-984-4218</phone>
    <email>jennifer.sisler@aesculapbiologics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Collins</last_name>
    <phone>310-948-8400</phone>
    <email>sarah.collins@aesculapbiologics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Wright</last_name>
      <phone>614-293-2410</phone>
    </contact>
    <investigator>
      <last_name>David Flanigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpine Orthopaedics</name>
      <address>
        <city>North Logan</city>
        <state>Utah</state>
        <zip>84341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>435-774-8512</phone>
    </contact>
    <investigator>
      <last_name>Brad Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrials.gov/ct2/show/NCT01957722?term=novocart+3d&amp;rank=1</url>
    <description>Main Clinical Study AAG-G-H-1220</description>
  </link>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 13, 2017</study_first_submitted>
  <study_first_submitted_qc>July 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cartilage repair</keyword>
  <keyword>cartilage regeneration</keyword>
  <keyword>cartilage reconstruction</keyword>
  <keyword>cartilage restoration</keyword>
  <keyword>autologous chondrocyte implantation</keyword>
  <keyword>matrix associated chondrocyte implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cartilage Diseases</mesh_term>
    <mesh_term>Fractures, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

